Features Partner Sites Information LinkXpress
Sign In
Demo Company

Strategy Found to Delay Age-Related Disorders

By BiotechDaily International staff writers
Posted on 22 Nov 2011
Print article
Scientists have demonstrated that eliminating cells that accrue with age could prevent or delay the onset of age-related disorders and disabilities. The research, conducted in mouse models, provides the first evidence that these cells could contribute to aging and suggests a way to help people stay healthier as they age.

The findings were published November 2, 2011, in the journal Nature, along with an independent commentary on the discovery. “By attacking these cells and what they produce, one day we may be able to break the link between aging mechanisms and predisposition to diseases like heart disease, stroke, cancers, and dementia,” remarked coauthor James Kirkland, MD, PhD, head of the Mayo Clinic’s (Rochester, MN, USA) Robert and Arlene Kogod Center on Aging, and a professor of aging research. “There is potential for a fundamental change in the way we provide treatment for chronic diseases in older people.”

Fifty years ago, scientists discovered that cells undergo a finite number of divisions before they stop dividing. At that point, the cells reach a state called cellular senescence where they neither die nor continue to multiply. They produce factors that injure adjacent cells and cause tissue inflammation. This alternate cell fate is believed to be a mechanism to prevent runaway cell growth and the spread of cancer. The immune system sweeps out these dysfunctional cells on a regular basis, but over time becomes less effective at “keeping house.”

As a result, senescent cells accumulate with age. Whether and how these cells cause age-related diseases and dysfunction has been a major open question in the field of aging. One reason the question has been so difficult to answer is that the numbers of senescent cells are quite limited and comprise at most only 10% to 15% of cells in an elderly individual.

“Our discovery demonstrates that in our body cells are accumulating that cause these age-related disorders and discomforts,” noted senior author Jan van Deursen, PhD, a Mayo Clinic molecular biologist and professor of cellular senescence. “Therapeutic interventions to get rid of senescent cells or block their effects may represent an avenue to make us feel more vital, healthier, and allow us to stay independent for a much longer time.”

“Through their novel methodology, the researchers discovered that deletion of senescent cells in genetically engineered mice led to improvement in at least some aspects of the physiology of these animals. So, with the caveat that the study involved a mouse model displaying accelerated aging, this paper provides important insights on aging at the cellular level,” said Felipe Sierra, PhD, director of the division of aging biology, US National Institute on Aging, National Institutes of Health (Bethesda, MD, USA).

Dr. van Deursen and colleagues genetically modified mice so their senescent cells harbored a molecule called caspase 8 that was only activated in the presence of a drug that has no effect on normal cells. When the transgenic mice were exposed to this drug, caspase 8 was triggered in the senescent cells, drilling holes in the cell membrane to destroy the senescent cells specifically.

The researchers discovered that lifelong elimination of senescent cells delayed the onset of age-related disorders such as cataracts, muscle loss, and weakness. Possibly, even more significantly, they showed that taking out these cells later in life could slow the progression of already established age-related disorders.

The findings, according to the researchers, validate a role of senescent cells in the aging process and demonstrate that chemicals secreted by these cells contribute to age-related tissue dysfunction and disease.

Related Links:

Mayo Clinic

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.